摘要
目的探讨抑亢丸联合丙硫氧嘧啶治疗甲状腺功能亢进症的临床疗效。方法选取2018年1月—2020年1月在驻马店市中心医院治疗的甲状腺功能亢进症患者86例,随机分为对照组(43例)和治疗组(43例)。对照组口服丙硫氧嘧啶片,初始剂量100 mg/次,3次/d,服用半个月后,根据甲状腺功能指标调整剂量为50 mg/次,3次/d。治疗组在对照组基础上口服抑亢丸,6 g/次,2次/d。两组均连续治疗2个月。观察两组患者临床疗效,同时比较治疗前后两组患者血清游离三碘甲腺原氨酸(FT3)、血清游离甲状腺素(FT4)、三碘甲状腺原氨酸(T3)和甲状腺素(T4)水平,及不良反应情况。结果治疗后,对照组和治疗组临床有效率分别为76.74%和93.02%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者FT3、FT4、T3、T4水平均显著降低(P<0.05),且治疗组显著低于对照组(P<0.05)。治疗期间,对照组患者药物不良反应发生率为46.51%,显著高于治疗组的16.28%,两组比较差异具有统计学意义(P<0.05)。结论抑亢丸联合丙硫氧嘧啶治疗甲状腺功能亢进可明显改善临床症状,促进甲状腺功能指标的恢复,且不良反应低。
Objective To investigate the curative effect of Yikang Pills combined with prothiouracil in treatment of hyperthyroidism.Methods Patients(86 cases)with hyperthyroidism in Zhumadian Central Hospital from January 2018 to January 2020 were randomly divided into control(43 cases)and treatment(43 cases)groups.Patients in the control group were po administered with Propylthiouracil Tablets,the initial dose was 100 mg/time,three times daily,and the dose was adjusted to 50 mg/time after 15 d,three times daily.Patients in the treatment group were po administered with Yikang Pills on the basis of the control group,6 g/time,twice daily.Patients in two groups were treated for 2 months.After treatment,the clinical efficacy was evaluated,and the levels of FT3,FT4,T3 and T4,and adverse reactions in two groups before and after treatment were compared.Results After treatment,the clinical efficacy and in the control and treatment groups was 76.74%and 93.02%respectively,and there were differences between two groups(P<0.05).After treatment,the levels of FT3,FT4,T3 and T4 in two groups were significantly decreased(P<0.05),and these thyroid function indexes in the treatment group were significantly lower than those in the control group(P<0.05).During the treatment,the adverse reactions rate in the control group was 46.51%,which was significantly higher than 16.28%in treatment the group,with significant difference between two groups(P<0.05).Conclusion Yikang Pills combined with propylthiouracil in treatment of hyperthyroidism can significantly improve the clinical symptoms,promote the recovery of thyroid function with less adverse reactions.
作者
田艳娟
李万森
高大红
杨小东
胡艳红
张会峰
TIAN Yan-juan;LI Wan-sen;GAO Da-hong;YANG Xiao-dong;HU Yan-hong;ZHANG Hui-feng(Department of General Medical,Zhumadian Central Hospital,Zhumadian,463000,China;Department of Endocrinology,Henan Provincial People's Hospital,Zhengzhou 450003,China)
出处
《现代药物与临床》
CAS
2020年第8期1588-1591,共4页
Drugs & Clinic
基金
河南省科技研发专项项目(172102310044)。